Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cizutamig Absolute Bioavailability in Healthy Participants
NCT07236411Phase 1Completed
- Sponsor
- Candid Therapeutics
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cizutamig (4 arms), sponsored by Candid Therapeutics. Primary endpoint: Absolute bioavailability. Started Dec 2025; status: completed.
02
Drugs
cizutamig
Beyond the preview
Go deeper on NCT07236411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07236411.